

# Jacqueline Barrientos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/487339/publications.pdf>

Version: 2024-02-01

92  
papers

10,106  
citations

201674

27  
h-index

69250

77  
g-index

93  
all docs

93  
docs citations

93  
times ranked

8242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination. <i>BMJ Case Reports</i> , 2022, 15, e247022.	0.5	8
2	Activated CLL cells regulate IL-17Fâ€producing Th17 cells in miR155-dependent and outcome-specific manners. <i>JCI Insight</i> , 2022, 7, .	5.0	2
3	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. <i>Leukemia and Lymphoma</i> , 2021, 62, 837-845.	1.3	1
4	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	4.8	11
5	Oral PI3K-Î³ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2109-2119.	2.0	9
6	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	7.2	25
7	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
8	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	2.8	12
9	Henoch-Schœnlein purpura presenting post COVID-19 vaccination. <i>Vaccine</i> , 2021, 39, 4571-4572.	3.8	41
10	COVID-19 infection presenting as paroxysmal nocturnal hemoglobinuria. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04636.	0.5	7
11	Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL. <i>Blood</i> , 2021, 138, 2625-2625.	1.4	0
12	Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue. <i>Blood</i> , 2021, 138, 3708-3708.	1.4	0
13	Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3534-3534.	1.4	1
14	Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL. <i>Blood</i> , 2021, 138, 2622-2622.	1.4	0
15	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 174-183.e3.	0.4	21
16	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.8	40
17	Chemotherapy-free frontline therapy for CLL: is it worth it?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 24-32.	2.5	12
18	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.2	67

#	ARTICLE	IF	CITATIONS
19	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 438-444.e1.	0.4	18
20	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
21	CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. <i>Blood Advances</i> , 2020, 4, 893-905.	5.2	5
22	Cirtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	5
23	Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry. <i>Blood</i> , 2020, 136, 42-43.	1.4	5
24	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	27.0	545
25	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	4.1	305
26	Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 487-498.	3.8	9
27	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1391-1402.	1.6	177
28	Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. <i>Journal of Immunology</i> , 2019, 202, 2924-2944.	0.8	9
29	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	4.1	27
30	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.2	90
31	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 1000-1005.	1.3	17
32	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
33	CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019, 134, 477-477.	1.4	4
34	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	1.4	1
35	Can umbralisib bring PI3K $\gamma$ out of the shadows?. <i>Lancet Oncology</i> , The, 2018, 19, 432-434.	10.7	5
36	Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2018, 2, e39.	2.7	12

#	ARTICLE	IF	CITATIONS
37	Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion. <i>Journal of Immunology</i> , 2018, 201, 1570-1585.	0.8	16
38	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.4	32
39	Dual Inhibition of PI3K- $\hat{1}$ and PI3K- $\hat{3}$ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model. <i>Blood</i> , 2018, 132, 4420-4420.	1.4	4
40	Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo. <i>Blood</i> , 2018, 132, 3124-3124.	1.4	0
41	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	10.7	287
42	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
43	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017, 129, 2581-2584.	1.4	161
44	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	1.4	243
45	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	1.4	111
46	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
47	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2016, 1, 122-131.	5.2	15
48	Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. <i>Stem Cell Investigation</i> , 2016, 3, 27-27.	3.0	18
49	Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. <i>OncoTargets and Therapy</i> , 2016, 9, 2945.	2.0	24
50	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016, 1, .	5.0	29
51	Sequencing of chronic lymphocytic leukemia therapies. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 128-136.	2.5	14
52	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
53	Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Future Oncology</i> , 2016, 12, 2077-2094.	2.4	9
54	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785

#	ARTICLE	IF	CITATIONS
55	Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. <i>Leukemia</i> , 2016, 30, 74-85.	7.2	5
56	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	1.4	4
57	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	1.4	9
58	Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment. <i>Blood</i> , 2016, 128, 2770-2770.	1.4	26
59	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	1.4	7
60	Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group. <i>Blood</i> , 2016, 128, 4373-4373.	1.4	0
61	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	1.4	349
62	Management of Chronic Lymphocytic Leukemia in the Elderly. <i>Cancer Control</i> , 2015, 22, 17-23.	1.8	22
63	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015, 56, 2779-2786.	1.3	268
64	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
65	Characterization of Atrial Fibrillation and Bleeding Risk Factors in Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US). <i>Blood</i> , 2015, 126, 3301-3301.	1.4	3
66	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation. <i>Blood</i> , 2015, 126, 4155-4155.	1.4	8
67	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015, 126, 830-830.	1.4	38
68	Ibrutinib for Transformed Lymphoma; A Report of 4 Patients. <i>Blood</i> , 2015, 126, 5115-5115.	1.4	0
69	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	27.0	1,535
70	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
71	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 42-48.	1.4	60
72	CLL Sera Drive Maturation of Normal Monocytes to M2-like Macrophages By Direct and Indirect Mechanisms. <i>Blood</i> , 2014, 124, 1970-1970.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	1.4	32
74	TLR-9 and IL-15-Driven Clonal Expansion of B-CLL Cells. <i>Blood</i> , 2014, 124, 1937-1937.	1.4	0
75	Reciprocal Densities of CXCR4 and CD5 Define Subfractions of Chronic Lymphocytic Leukemia Clones Differing in Phenotype and Response to Environmental Stimuli: Towards a Better Definition of Targetable Components of Leukemic Clones. <i>Blood</i> , 2014, 124, 3322-3322.	1.4	0
76	Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1817-1820.	1.3	15
77	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
78	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3K $\hat{\imath}$ , In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation. <i>Blood</i> , 2013, 122, 1632-1632.	1.4	12
79	Idelalisib, a Selective Inhibitor Of PI3K $\hat{\imath}$ , In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2878-2878.	1.4	14
80	Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability. <i>Blood</i> , 2013, 122, 4176-4176.	1.4	6
81	A Phase 1 Study Of The Selective PI3K $\hat{\imath}$ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4180-4180.	1.4	10
82	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, LBA-6-LBA-6.	1.4	4
83	Apparent Involvement Of The Interferon, RNA Processing, and Wnt Signaling Pathways In Monoclonal B Lymphocytosis. <i>Blood</i> , 2013, 122, 4157-4157.	1.4	0
84	Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation. <i>Blood</i> , 2013, 122, 2583-2583.	1.4	0
85	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 119-119.	1.4	1
86	Concomitant, T-Independent TLR9-Mediated and BCR-Mediated Activation Provides Signals For Optimal Telomerase Induction In Chronic Lymphocytic Leukemia Cells Regardless Of IGHV Mutation Status. <i>Blood</i> , 2013, 122, 4142-4142.	1.4	0
87	Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. <i>Blood</i> , 2012, 120, 191-191.	1.4	15
88	Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K $\hat{\imath}$ ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study. <i>Blood</i> , 2012, 120, 3645-3645.	1.4	5
89	Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 316-316.	1.4	0
90	CLL Cells Can Diversify, Switch, and Differentiate in Response to Autologous T Cell Stimuli Present in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 315-315.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. Blood, 2012, 120, 2545-2545.	1.4	4
92	CLL Cell Viability Promoted by Myosin Heavy Chain IIA Exposed Apoptotic Cells is BTK-dependent. Blood, 2012, 120, 1767-1767.	1.4	0